Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8102 USD | -3.55% | -2.19% | +42.14% |
Business Summary
Number of employees: 40
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Rothera
CEO | Chief Executive Officer | 62 | 18/09/22 |
Melody Burcar
DFI | Director of Finance/CFO | 41 | 31/08/22 |
Chief Tech/Sci/R&D Officer | - | - | |
Darrel Cohen
CTO | Chief Tech/Sci/R&D Officer | 59 | 06/08/23 |
Ayman El-Guindy
CTO | Chief Tech/Sci/R&D Officer | - | 05/07/21 |
Ivor Royston
BRD | Director/Board Member | 79 | 30/09/07 |
Ashleigh Barreto
IRC | Investor Relations Contact | - | 30/09/21 |
Corporate Officer/Principal | - | 05/07/21 | |
Patric Nelson
PRN | Corporate Officer/Principal | - | 05/07/21 |
Cheryl A. Madsen
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ivor Royston
BRD | Director/Board Member | 79 | 30/09/07 |
Thomas Darcy
BRD | Director/Board Member | 74 | 31/01/21 |
Barry Simon
BRD | Director/Board Member | 69 | 02/03/21 |
Mark Rothera
CEO | Chief Executive Officer | 62 | 18/09/22 |
Roger Pomerantz
CHM | Chairman | 67 | 31/05/20 |
Flavia Borellini
BRD | Director/Board Member | 65 | 13/08/21 |
Jane Barlow
BRD | Director/Board Member | 63 | 13/08/21 |
Stephen Rubino
BRD | Director/Board Member | 65 | 02/03/21 |
Sam Murphy
BRD | Director/Board Member | - | 31/12/18 |
Jane Chung
BRD | Director/Board Member | 53 | 09/08/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 39,272,434 | 38,184,370 ( 97.23 %) | 0 | 97.20 % |
Stock B | 0 | 10,248 | 0 | 0 |
Company contact information
Viracta Therapeutics, Inc.
2533 South Coast Highway 101 Suite 210
92007, Cardiff
+
http://www.viracta.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.14% | 31.82M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- VIRX Stock
- Company Viracta Therapeutics, Inc.